[ 1 ] Antibody therapeutics approved or in regulatory review in the EU or US [Internet]. Framingham: The Antibody Society; 2015 [cited 2021 Sep 16]. Available from: https://www.antibodysociety.org/resources/approvedantibodies/.

[ 2 ] Hutchings CJ, Koglin M, Olson WC, Marshall FH. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov 2017;16(11):787–810. link1

[ 3 ] Hutchings CJ, Colussi P, Clark TG. Ion channels as therapeutic antibody targets. MAbs 2019;11(2):265–96. link1

[ 4 ] Dodd RB, Wilkinson T, Schofield DJ. Therapeutic monoclonal antibodies to complex membrane protein targets: antigen generation and antibody discovery strategies. BioDrugs 2018;32:339–55. link1

[ 5 ] Douthwaite JA, Finch DK, Mustelin T, Wilkinson TC. Development of therapeutic antibodies to G protein-coupled receptors and ion channels: opportunities, challenges and their therapeutic potential in respiratory diseases. Pharmacol Ther 2017;169:113–23. link1

[ 6 ] Wilkinson TC, Gardener MJ, Williams WA. Discovery of functional antibodies targeting ion channels. J Biomol Screen 2015;20(4):454–67. link1

[ 7 ] Wulff H, Christophersen P, Colussi P, Chandy KG, Yarov-Yarovoy V. Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov 2019;18(5):339–57. link1

[ 8 ] Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov 2017;16 (1):19–34. link1

[ 9 ] Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, et al. Unexplored therapeutic opportunities in the human genome. Nat Rev Drug Discov 2018;17(5):317–32. link1

[10] Kasamon YL, Chen H, de Claro RA, Nie L, Ye J, Blumenthal GM, et al. FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and Sézary syndrome. Clin Cancer Res 2019;25(24):7275–80. link1

[11] Shreiber AM. Erenumab (Aimovig) for migraine prophylaxis in adults. Am Fam Physician 2019;99(12):781–2. link1

[12] Gilbert SM, Gidley Baird A, Glazer S, Barden JA, Glazer A, Teh LC, et al. A phase I clinical trial demonstrates that nfP2X7-targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol 2017;177(1):117–24. link1

[13] Biswas K, Nixey TE, Murray JK, Falsey JR, Yin L, Liu H, et al. Engineering antibody reactivity for efficient derivatization to generate NaV1.7 inhibitory GpTx-1 peptide-antibody conjugates. ACS Chem Biol 2017;12(9):2427–35. link1

[14] Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012;4(4):419–25. link1

[15] Weierstall U, James D, Wang C, White TA, Wang D, Liu W, et al. Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography. Nat Commun 2014;5(1):3309. link1

[16] Boshuizen RS, Marsden C, Turkstra J, Rossant CJ, Slootstra J, Copley C, et al. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2). MAbs 2014;6(6):1415–24. link1

[17] Fujimoto A, Kosaka N, Hasegawa H, Suzuki H, Sugano S, Chiba J. Enhancement of antibody responses to native G protein-coupled receptors using E. coli GroEL as a molecular adjuvant in DNA immunization. J Immunol Methods 2012;375 (1–2):243–51. link1

[18] Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, et al. Defucosylated antiCCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R cnull mice in vivo. J Immunol 2009;183(7):4782–91. link1

[19] Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004;64(6):2127–33. link1

[20] Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010;16(5):1520–31. link1

[21] Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2006;50 (10):3289–96. link1

[22] Olson WC, Rabut GEE, Nagashima KA, Tran DNH, Anselma DJ, Monard SP, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999;73(5):4145–55. link1

[23] Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001;75(2):579–88. link1

[24] Shearer WT, DeVille JG, Samson PM, Moye Jr JH, Fletcher CV, Church JA, et al. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). J Allergy Clin Immunol 2006;118(2):518–21. link1

[25] Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 2016;356(1):223–31. link1

[26] Xu C, Shi L, Rao S, King C, Sun H, Zhu D, et al. EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain 2014;15(S1):G43. link1

[27] Amgen. Study to evaluate the efficacy and safety of Erenumab (AMG 334) in migraine prevention [Internet]. Bethesda: US National Library of Medicine; [updated 2019 Oct 9; cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02456740.

[28] Amgen. Study to evaluate the efficacy and safety of Erenumab (AMG 334) compared to placebo in migraine prevention [Internet]. Bethesda: US National Library of Medicine; [updated 2019 Dec 11; cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02483585.

[29] Amgen. A study to evaluate the efficacy and safety of Erenumab (AMG 334) in chronic migraine prevention [Internet]. Bethesda: US National Library of Medicine; [updated 2019 Dec 17; cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02066415.

[30] Innate Pharma. IPH5401 (Anti-C5aR) in combination with Durvalumab in patients with advanced solid tumors [Internet]. Bethesda: US National Library of Medicine; [updated 2019 Dec 23; cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03665129.

[31] Bionomics Limited. A phase I, dose escalation study of BNC101 in patients with metastatic colorectal cancer [Internet]. Bethesda: US National Library of Medicine; [updated 2019 Jan 16; cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02726334.

[32] Merus NV. A study of bispecific antibody MCLA-158 in patients with advanced solid tumors [Internet]. Bethesda: US National Library of Medicine; [updated 2018 Aug 13; cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/ show/NCT03526835.

[33] Beijing Dongfang Biotech Co., Ltd. A study of JY09 in Chinese healthy subjects [Internet]. Bethesda: US National Library of Medicine; [updated 2016 Dec 7; cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02971722.

[34] Bird Rock Bio, Inc. Study to evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of Nimacimab in patients with diabetic gastroparesis [Internet]. Bethesda: US National Library of Medicine; [updated 2020 Jan 18; cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/show/ NCT03900325.

[35] Kashyap MK, Jones H, Sabbatini P, Kipps TJ, Shelat SG, Choi MY, et al. Ulocuplumab (BMS-936564/MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 2015;7(3):2809–22. link1

[36] Lin FF, Elliott R, Colombero A, Gaida K, Kelley L, Moksa A, et al. Generation and characterization of fully human monoclonal antibodies against human Orai1 for autoimmune disease. J Pharmacol Exp Ther 2013;345(2):225–38. link1

[37] Cox JH, Hussell S, Sondergaard H, Roepstorff K, Bui JV, Deer JR, et al. Antibodymediated targeting of the Orai1 calcium channel inhibits T cell function. PLoS ONE 2013;8(12):e82944. link1

[38] Tucker DF, Sullivan JT, Mattia KA, Fisher CR, Barnes T, Mabila MN, et al. Isolation of state-dependent monoclonal antibodies against the 12- transmembrane domain glucose transporter 4 using virus-like particles. Proc Natl Acad Sci USA 2018;115(22):E4990–9. link1

[39] Nam DH, Rodriguez C, Remacle AG, Strongin AY, Ge X. Active-site MMPselective antibody inhibitors discovered from convex paratope synthetic libraries. Proc Natl Acad Sci USA 2016;113(52):14970–5. link1

[40] Ma Y, Ding Y, Song X, Ma X, Li X, Zhang N, et al. Structure-guided discovery of a single-domain antibody agonist against human apelin receptor. Sci Adv 2020;6(3):eaax7379. link1

[41] Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, et al. Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem 2007;282(8):5116–24. link1

[42] Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, et al. Adrenalineactivated structure of b2-adrenoceptor stabilized by an engineered nanobody. Nature 2013;502(7472):575–9. link1

[43] Webb DR, Handel TM, Kretz-Rommel A, Stevens RC. Opportunities for functional selectivity in GPCR antibodies. Biochem Pharmacol 2013;85 (2):147–52. link1

[44] GPCR [Internet]. Cambridge: Nature Education; c2014 [cited 2019 Dec 16]. Available from: https://www.nature.com/scitable/topicpage/gpcr-14047471/.

[45] Ion channel [Internet]. Cambridge: Nature Education; c2014 [cited 2019 Dec 16]. Available from: https://www.nature.com/scitable/topicpage/ion-channel14047658/.

[46] Ohta S, Sakaguchi S, Kobayashi Y, Mizuno N, Tago K, Itoh H. Agonistic antibodies reveal the function of GPR56 in human glioma U87-MG cells. Biol Pharm Bull 2015;38(4):594–600. link1

[47] Hutchings CJ, Cseke G, Osborne G, Woolard J, Zhukov A, Koglin M, et al. Monoclonal anti-b1-adrenergic receptor antibodies activate G protein signaling in the absence of beta-arrestin recruitment. MAbs 2014;6 (1):246–61. link1

[48] Ullmer C, Zoffmann S, Bohrmann B, Matile H, Lindemann L, Flor P, et al. Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7. Br J Pharmacol 2012;167(7):1448–66. link1

[49] Konitzer JD, Pramanick S, Pan Q, Augustin R, Bandholtz S, Harriman W, et al. Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor. MAbs 2017;9(3):536–49. link1

[50] FDA approves treatment for two rare types of non-Hodgkin lymphoma [Internet]. Silver Spring: US Food and Drug Administration; 2018 Aug 18 [cited 2020 Feb 20]. Available from: https://www.fda.gov/news-events/pressannouncements/fda-approves-treatment-two-rare-types-non-hodgkinlymphoma.

[51] Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, et al. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res 2015;21(2):274–85. link1

[52] Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014;32 (11):1157–63. link1

[53] Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev 2009;231(1):59–87. link1

[54] Geoghegan JC, Diedrich G, Lu X, Rosenthal K, Sachsenmeier KF, Wu H, et al. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, noncompetitive mechanism of action. MAbs 2016;8(3):454–67. link1

[55] Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. The G-protein-coupled receptors in the human genome form five main families. Mol Pharmacol 2003;63(6):1256–72. link1

[56] Hu GM, Mai TL, Chen CM. Visualizing the GPCR Network: classification and evolution. Sci Rep 2017;7(1):15495. link1

[57] Zhang Y, Pool C, Sadler K, Yan HP, Edl J, Wang X, et al. Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides. Biochemistry 2004;43(39):12575–84. link1

[58] Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S, et al. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 1998;92 (10):3521–8. link1

[59] Qiang M, Dong X, Zha Z, Zuo XK, Song XL, Zhao L, et al. Selection of an ASIC1ablocking combinatorial antibody that protects cells from ischemic death. Proc Natl Acad Sci USA 2018;115(32):E7469–77. link1

[60] Mettler Izquierdo S, Varela S, Park M, Collarini EJ, Lu D, Pramanick S, et al. High-efficiency antibody discovery achieved with multiplexed microscopy. Microscopy 2016;65(4):341–52. link1

[61] MacDonald L, Gao M, Morra M, Alessandri-Haber NM, LaCroix-Fralish ML, inventors; Regeneron Pharmaceuticals, Inc., assignee. Anti-ASIC1 antibodies and uses thereof. United States patent US 9371383B2. 2016 Jun 21.

[62] Stortelers C, Pinto-Espinoza C, Van Hoorick D, Koch-Nolte F. Modulating ion channel function with antibodies and nanobodies. Curr Opin Immunol 2018;52:18–26. link1

[63] Li LH, Shivakumar R, Feller S, Allen C, Weiss JM, Dzekunov S, et al. Highly efficient, large volume flow electroporation. Technol Cancer Res Treat 2002;1 (5):343–9. link1

[64] Sasaki Y, Kosaka H, Usami K, Toki H, Kawai H, Shiraishi N, et al. Establishment of a novel monoclonal antibody against LGR5. Biochem Biophys Res Commun 2010;394(3):498–502. link1

[65] Danquah W, Rissiek B, Pinto C, Arnau SP, Amadi M, Iacenda D, et al. Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci Transl Med 2016;8(366):366ra162. link1

[66] Robertson N, Jazayeri A, Errey J, Baig A, Hurrell E, Zhukov A, et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology 2011;60(1):36–44. link1

[67] Tehan BG, Christopher JA. The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniques. Curr Opin Pharmacol 2016;30:8–13. link1

[68] Denisov IG, Sligar SG. Nanodiscs for structural and functional studies of membrane proteins. Nat Struct Mol Biol 2016;23(6):481–6. link1

[69] Lindhoud S, Carvalho V, Pronk JW, Aubin-Tam ME. SMA-SH: modified styrenemaleic acid copolymer for functionalization of lipid nanodiscs. Biomacromolecules 2016;17(4):1516–22. link1

[70] Schmidt V, Sturgis JN. Modifying styrene-maleic acid co-polymer for studying lipid nanodiscs. Biochim Biophys Acta Biomembr 2018;1860(3):777–83. link1

[71] Van der Woning B, de Boeck G, Blanchetot C, Bobkov V, Klarenbeek A, Saunders M, et al. DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops. MAbs 2016;8(6):1126–35. link1

[72] Frauenfeld J, Loving R, Armache JP, Sonnen AF, Guettou F, Moberg P, et al. A saposin-lipoprotein nanoparticle system for membrane proteins. Nat Methods 2016;13(4):345–51. link1

[73] Bergmann-Leitner ES, Leitner WW. Vaccination using gene-gun technolog. In: Vaughan A, editor. Malaria vaccines: methods and protocols. New York: Humana Press; 2015. p. 289–302. link1

[74] Hansen DT, Craciunescu FM, Fromme P, Johnston SA, Sykes KF. Generation of high-specificity antibodies against membrane proteins using DNA–gold micronanoplexes for gene gun immunization. Curr Protoc Protein Sci 2018;91(1):29.20.1–22. link1

[75] Harris GL, Creason MB, Brulte GB, Herr DR. In vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody. PLoS ONE 2012;7(4):1–8. link1

[76] Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155 (4):1280–90. link1

[77] Hennen S, Kodra JT, Soroka V, Krogh BO, Wu X, Kaastrup P, et al. Structural insight into antibody-mediated antagonism of the glucagon-like peptide-1 receptor. Sci Rep 2016;6(1):26236. link1

[78] Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA 2014;111 (14):5153–8. link1

[79] Douthwaite JA, Sridharan S, Huntington C, Hammersley J, Marwood R, Hakulinen JK, et al. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1. MAbs 2015;7(1):152–66. link1

[80] Dufton N, Perretti M. Therapeutic anti-inflammatory potential of formylpeptide receptor agonists. Pharmacol Ther 2010;127(2):175–88. link1

[81] Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther 2009;329(1):102–11. link1

[82] Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, et al. BMS-936564/ MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 2013;19(2):357–66. link1

[83] Low S, Wu H, Jerath K, Tibolla A, Fogal B, Conrad R, et al. VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis. MAbs 2020;12(1):1709322. link1

[84] Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495–7. link1

[85] Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment. Drug Des Devel Ther 2009;3:7–16. link1

[86] Jahnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci USA 2010;107(47):20565–70. link1

[87] Robert R, Juglair L, Lim EX, Ang C, Wang CJH, Ebert G, et al. A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6. PLoS ONE 2017;12(9):e0184278. link1

[88] Gong X, Azhdarinia A, Ghosh SC, Xiong W, An Z, Liu Q, et al. LGR5-targeted antibody-drug conjugate eradicates gastrointestinal tumors and prevents recurrence. Mol Cancer Ther 2016;15(7):1580–90. link1

[89] Kretz-Rommel A, Shi L, Ferrini R, Yang T, Xu F, Campion B, inventors; Ruiyi Inc., assignee. Antibodies that bind human cannabinoid 1 (CB1) receptor. United States patent US 2015/023108. 2015 Oct 1.

[90] Williams MS, Charles ML, inventors; DiaMedica Inc, Williams MS, Charles ML, assignees. Anti-bradykinin B2 receptor (BKB2R) monoclonal antibody. United States patent US 2011/062967 2012 Jun 7.